Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Document › Details

Thermosome GmbH. (4/6/16). "Press Release: Thermosome Receives €2.7m Research Grant from the German Federal Ministry of Education and Research (BMBF)". Martinsried.

Region Region Germany
Organisations Organisation Thermosome GmbH
  Organisation 2 BMBF (Federal Ministry for Education and Research) (DE)
  Group Germany (govt)
Products Product TSL technology (thermosensitive nano drug encapsulation technology)
  Product 2 business development (state/region)
Index term Index term Thermosome–Germany (govt): grant, 201604– BMBF grant €2.7m 3y as part of TSL-LIFU project consortium
Person Person Schweizer, Pascal (Thermosome GmbH 201604 Managing Director)

Thermosome GmbH, an emerging biopharmaceutical company, today announces the final approval of a €2.7m grant from the German Ministry of Education and Research (BMBF) over the project duration of 3 years. The contribution to Thermosome is part of a larger project consortium called “TSL-LIFU” (temperature-sensitive liposomes - low-intensity focused ultrasound), which was approved under the BMBF call “Efficient drug delivery in biological systems (BioMatVital: BioTransporter)”. The consortium aims to significantly advance a novel drug-device combination for targeted delivery of cytotoxic drugs in solid tumors. Besides Thermosome, the project consortium consists of Philips, the University Hospital of the Ludwig-Maximilians-Universitaet Munich (KUM) and the University Hospital Cologne (UHC) and is supported with a total grant volume of approximately €4.2m over 3 years.

Within the consortium, Thermosome and KUM will conduct further research in the area of thermosensitive drug delivery technologies and thereof derived drug candidates, leveraging Thermosome’s novel TSL technology. This technology allows the creation of drug-loaded nanocarriers – so-called Thermosomes – which release their content upon the influence of mild heat. Philips and UHC will conduct further research in the application of high intensity focused ultrasound (HIFU®) technology for hyperthermia applications at lower temperatures of about 40-42°C, so-called low-intensity focused ultrasound (LIFU). If successful, LIFU may one day be clinically used to trigger targeted drug delivery from Thermosome’s TSL nanocarriers. Overall, the consortium aims to advance these very promising technologies towards a clinical application with the long-term goal of adding improved therapeutic options for patients with solid tumors.

Thermosome’s managing director, Dr. Pascal Schweizer, comments: “We are grateful of the strong support of the BMBF, which approved this very substantial grant providing about €4.2m to the TSL-LIFU project consortium. We are confident that our consortium combines strong partners with in-depth expertise from industry and academia and covers all needed competences, both within drug development and hyperthermia devices.“

Media contact

Thermosome GmbH
Dr. Pascal Schweizer
Managing Director & Chief Financial Officer (CFO)
+49 (0)89 7167760-31

About Thermosome

Thermosome® is an emerging biopharmaceutical company leveraging its proprietary drug delivery technology platform for drug development. Through its TSL technology, drug-loaded nanocarriers – so-called Thermosomes – can be created which release their content upon the influence of mild heat. Administered intraveneously, the drug load is instantly released from Thermosomes at non-harming temperatures of 40-42°C, achieved by various clinically established targeted heating techniques such as microwave or ultrasound. With our Thermosomes, up to 15 fold higher local drug concentrations can be reached while simultaneously reducing the systemic exposure and side effects of these drugs (compared to conventional parenteral drug application). Through this novel technology, Thermosome aims to significantly enlarge the therapeutic and safety window of these drugs and reach improved therapeutic outcomes. Thermosome’s lead candidate, a formulation of a potent, but highly toxic chemotherapeutic drug, is currently in pre-clinical development and shall be moved into clinical development against certain solid tumors in the future. For more information, visit

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2015 sales of EUR 24.2 billion and employs approximately 104,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at

About the University Hospital of the Ludwig-Maximilians-Universitaet Munich

The University Hospital of the Ludwig-Maximilians-Universitaet Munich is a center of high-end medicine, medical innovation and research. With more than 2,000 beds, it is a highly advanced hospital with 45 clinics, institutes and departments covering all fields of medicine. With its two campuses in Grosshadern and in the city center, it is one of the largest hospitals in Europe. The Ludwig-Maximilians-Universitaet (LMU) Munich is the leading German University in the field „Clinical and health“ according to the Times Higher Education World University Ranking, and is constantly ranked among the best German research universities.

About University Clinic Cologne

The University Hospital Cologne is with 59 participating clinics and institutes, over 10,000 employees, and 1,300 patient beds one of Germany’s largest comprehensive cancer centers. A large variety of new and different therapeutic options are here established and in use for oncology care. The department of radiology contributes with state of the art imaging equipment and image guided interventions such as high intensity focussed ultrasound under MR-guidance. The HIFU technology is currently used for non-invaisve treatment of uterine fibroids and bone metastases and will be further developed for oncology applications such as local drug delivery in combination with low intensity focused ultrasound.

This communication contains certain forward-looking statements concerning Thermosome. The forward-looking statements contained herein represent the judgment of Thermosome as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. Thermosome does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Record changed: 2020-06-26


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Thermosome GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top